Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

Kang Min H.; Wang Jing; Makena Monish R.; Lee Joo-Sang; Paz Nancy; Hall Connor P.; Song Michael M.; Calderon Ruben I.; Cruz Riza E.; Hindle Ashly; Ko Winford; Fitzgerald Jonathan B.; Drummond Daryl C.; Triche Timothy J.; Reynolds C. Patrick

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

【24h】

Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

机译：尤文氏家族肿瘤异种移植物中MM-398，纳米脂质体伊立替康（nal-IRI）的活性与高剂量暴露于药物和高SLFN11表达的肿瘤有关

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: To determine the pharmacokinetics and the antitumor activity in pediatric cancer models of MM-398, a nanoliposomal irinotecan (nal-IRI).

机译：目的：确定纳米脂质体伊立替康（nal-IRI）MM-398在儿童癌症模型中的药代动力学和抗肿瘤活性。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2015年第5期|共12页
作者
Kang Min H.; Wang Jing; Makena Monish R.; Lee Joo-Sang; Paz Nancy; Hall Connor P.; Song Michael M.; Calderon Ruben I.; Cruz Riza E.; Hindle Ashly; Ko Winford; Fitzgerald Jonathan B.; Drummond Daryl C.; Triche Timothy J.; Reynolds C. Patrick;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
入库时间 2022-08-18 09:32:40

相似文献

外文文献
中文文献
专利

1. 高剂量表阿霉素在肿瘤患者中的药物动力学和药效学研究 [J] . 董梅, 冯奉仪, 付强癌症（英文版） . 2000,第004期
2. Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression [J] . Kang Min H., Wang Jing, Makena Monish R., Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第5期

机译：尤文氏家族肿瘤异种移植物中MM-398，纳米脂质体伊立替康（nal-IRI）的活性与高剂量暴露于药物和高SLFN11表达的肿瘤有关
3. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer [J] . Chiang Nai-Jung, Chang Jang-Yang, Shan Yan-Shen, Expert opinion on pharmacotherapy . 2016,第10期

机译：纳米脂质体伊立替康（nal-IRI，MM-398，PEP02）在转移性胰腺癌治疗中的开发
4. Longitudinal tumor hypoxia imaging with [ 18F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity [J] . Jinzi Zheng, Stephan G. Klinz, Raquel De Souza, EJNMMI Research . 2015,第4期

机译：纵向肿瘤缺氧成像与[ 18 f] faza-pet提供了纳米脂素伊替康（NAL-IRI）治疗活性的早期预测
5. Regulation of indoleamine 2,3-dioxygenase in an immunotherapy model for Ewing family tumors [C] . Max D., Kuhnol C D., Burdach S., European Congress of Immunology . 2009

机译：用于母鸡家族肿瘤的免疫疗法模型中吲哚胺2,3-二恶英酶的调节
6. BMI-1 expression inversely correlates with differentiation but not clinical outcome or CDKN2a expression in Ewing sarcoma family of tumors. [D] . van Doorninck, John Anthony. 2009

机译：BMI-1表达与尤因肉瘤家族中的分化呈负相关，但与临床结局或CDKN2a表达无关。
7. Longitudinal tumor hypoxia imaging with 18FFAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity [O] . Jinzi Zheng, Stephan G. Klinz, Raquel De Souza, 2015

机译：18F FAZA-PET纵向肿瘤缺氧成像可早期预测纳米脂质体伊立替康（nal-IRI）治疗活性
8. Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study [O] . D. Melisi, J.T. Siveke, J. Blanc, 2016

机译：纳米脂素氨基丙酮（NAL-IRI; MM-398）±5-氟尿嘧啶和裂凡蛋白（5-FU / LV）对患者（PTS）的寿命质量（QOL）的影响，所述牙吉三胺治疗方法（MPAC） - 基于治疗的疗法：第3阶段Napoli-1研究的结果

Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression

摘要

著录项

相似文献

相关主题

期刊订阅